Eric D. Whitman, MD to Present on the Delcath PHP System™ at the 7th World Congress on Melanoma

View printer-friendly version

NEW YORK, May 7, 2009 -- Delcath Systems, Inc., (Nasdaq: DCTH) a medical technology company testing its proprietary Percutaneous Hepatic Perfusion (PHP™) System for the treatment of cancers of the liver, announced today that Eric D. Whitman, MD, Director of the Atlantic Melanoma Center and a Principal Investigator of Delcath’s Phase III trial, will present at The 7th World Congress on Melanoma, to be held in Vienna, Austria, May 12-16, 2009.

Dr. Whitman’s presentation, titled Percutaneous Isolated Hepatic Perfusion for Cutaneous and Uveal Metastasic Melanoma, will discuss his experience with The Delcath PHP System™, as part of Delcath’s multi-center Phase III trial for metastatic melanoma, currently enrolling at twelve leading cancer centers throughout the United States.

This clinical study is testing the Delcath PHP System™ for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath PHP System™ is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while minimizing entry of the drugs into the rest of the patient's circulation. This isolation limits toxicities which result from systemic chemotherapy treatments.

Patients in the Phase III trial are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath PHP System™ or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), patients are permitted to "cross-over" from the best alternative care arm to receive treatment with the Delcath System at the time of disease progression.

Commenting on Dr. Whitman’s upcoming presentation, Richard L. Taney, President and CEO of Delcath Systems, stated, “As we move towards full enrollment of Delcath's pivotal Phase III Metastatic Melanoma Study, increasing the awareness of the Delcath PHP System™ and its use for metastatic melanoma becomes of even greater importance.  We are excited that Dr. Whitman will be sharing his experience with our System at such a prestigious conference and with such an international attendance.  We look forward to more opportunities such as these to continue informing the medical community about the Delcath System.”

About the World Melanoma Congress

The “World Congress on Melanoma” and the “Congress of the European Association of Dermato-Oncology” (EADO) have become major interdisciplinary meetings for clinicians and basic scientists working in the challenging fields of melanoma and non-melanoma skin cancer.  For the first time, both meetings will be held together as a Joint Meeting covering the entire spectrum of cutaneous malignancies.  Clinicians and researchers will focus on the state of the art in prevention, recognition, and treatment of cutaneous neoplasms covering melanoma and non melanoma skin cancer as well as lymphomas and rare skin tumors.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.